TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

A Jo Chien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.